116 related articles for article (PubMed ID: 36436079)
21. Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3.
Takaku M; Grimm SA; De Kumar B; Bennett BD; Wade PA
Nucleic Acids Res; 2020 May; 48(9):4756-4768. PubMed ID: 32232341
[TBL] [Abstract][Full Text] [Related]
22. Breast tumor specific mutation in GATA3 affects physiological mechanisms regulating transcription factor turnover.
Adomas AB; Grimm SA; Malone C; Takaku M; Sims JK; Wade PA
BMC Cancer; 2014 Apr; 14():278. PubMed ID: 24758297
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.
Severson TM; Nevedomskaya E; Peeters J; Kuilman T; Krijgsman O; van Rossum A; Droog M; Kim Y; Koornstra R; Beumer I; Glas AM; Peeper D; Wesseling J; Simon IM; Wessels L; Linn SC; Zwart W
Oncotarget; 2016 Jun; 7(23):33901-18. PubMed ID: 27129152
[TBL] [Abstract][Full Text] [Related]
24. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.
Millour J; Constantinidou D; Stavropoulou AV; Wilson MS; Myatt SS; Kwok JM; Sivanandan K; Coombes RC; Medema RH; Hartman J; Lykkesfeldt AE; Lam EW
Oncogene; 2010 May; 29(20):2983-95. PubMed ID: 20208560
[TBL] [Abstract][Full Text] [Related]
25. The antiviral drug telaprevir induces cell death by reducing FOXA1 expression in estrogen receptor α (ERα)-positive breast cancer cells.
Bartoloni S; Leone S; Pescatori S; Cipolletti M; Acconcia F
Mol Oncol; 2022 Oct; 16(19):3568-3584. PubMed ID: 36056637
[TBL] [Abstract][Full Text] [Related]
26. Interaction of glucocorticoid receptor (GR) with estrogen receptor (ER) α and activator protein 1 (AP1) in dexamethasone-mediated interference of ERα activity.
Karmakar S; Jin Y; Nagaich AK
J Biol Chem; 2013 Aug; 288(33):24020-34. PubMed ID: 23814048
[TBL] [Abstract][Full Text] [Related]
27. Estrogen induces dynamic ERα and RING1B recruitment to control gene and enhancer activities in luminal breast cancer.
Zhang Y; Chan HL; Garcia-Martinez L; Karl DL; Weich N; Slingerland JM; Verdun RE; Morey L
Sci Adv; 2020 Jun; 6(23):eaaz7249. PubMed ID: 32548262
[TBL] [Abstract][Full Text] [Related]
28. The estrogen receptor α is the key regulator of the bifunctional role of FoxO3a transcription factor in breast cancer motility and invasiveness.
Sisci D; Maris P; Cesario MG; Anselmo W; Coroniti R; Trombino GE; Romeo F; Ferraro A; Lanzino M; Aquila S; Maggiolini M; Mauro L; Morelli C; Andò S
Cell Cycle; 2013 Nov; 12(21):3405-20. PubMed ID: 24047697
[TBL] [Abstract][Full Text] [Related]
29. Estrogen induces repression of the breast cancer and salivary gland expression gene in an estrogen receptor alpha-dependent manner.
Bretschneider N; Brand H; Miller N; Lowery AJ; Kerin MJ; Gannon F; Denger S
Cancer Res; 2008 Jan; 68(1):106-14. PubMed ID: 18172302
[TBL] [Abstract][Full Text] [Related]
30. Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305.
Giordano C; Cui Y; Barone I; Ando S; Mancini MA; Berno V; Fuqua SA
Breast Cancer Res Treat; 2010 Jan; 119(1):71-85. PubMed ID: 19205871
[TBL] [Abstract][Full Text] [Related]
31. FOXA1 is a key determinant of estrogen receptor function and endocrine response.
Hurtado A; Holmes KA; Ross-Innes CS; Schmidt D; Carroll JS
Nat Genet; 2011 Jan; 43(1):27-33. PubMed ID: 21151129
[TBL] [Abstract][Full Text] [Related]
32. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.
Fu X; Jeselsohn R; Pereira R; Hollingsworth EF; Creighton CJ; Li F; Shea M; Nardone A; De Angelis C; Heiser LM; Anur P; Wang N; Grasso CS; Spellman PT; Griffith OL; Tsimelzon A; Gutierrez C; Huang S; Edwards DP; Trivedi MV; Rimawi MF; Lopez-Terrada D; Hilsenbeck SG; Gray JW; Brown M; Osborne CK; Schiff R
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):E6600-E6609. PubMed ID: 27791031
[TBL] [Abstract][Full Text] [Related]
33. Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
Salvati A; Melone V; Sellitto A; Rizzo F; Tarallo R; Nyman TA; Giurato G; Nassa G; Weisz A
Breast Cancer Res; 2022 Jul; 24(1):52. PubMed ID: 35850772
[TBL] [Abstract][Full Text] [Related]
34. Trans-acting non-synonymous variant of FOXA1 predisposes to hepatocellular carcinoma through modulating FOXA1-ERα transcriptional program and may have undergone natural selection.
Wang S; Xiang C; Mou L; Yang Y; Zhong R; Wang L; Sun C; Qin Z; Yang J; Qian J; Zhao Y; Wang Y; Pan X; Qie J; Jiang Y; Wang X; Yang Y; Zhou WP; Miao X; He F; Jin L; Wang H
Carcinogenesis; 2020 Apr; 41(2):146-158. PubMed ID: 31400761
[TBL] [Abstract][Full Text] [Related]
35. Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalpha.
Frietze S; O'Geen H; Littlepage LE; Simion C; Sweeney CA; Farnham PJ; Krig SR
BMC Genomics; 2014 Jun; 15(1):520. PubMed ID: 24962896
[TBL] [Abstract][Full Text] [Related]
36. Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity.
Cui Y; Zhang M; Pestell R; Curran EM; Welshons WV; Fuqua SA
Cancer Res; 2004 Dec; 64(24):9199-208. PubMed ID: 15604293
[TBL] [Abstract][Full Text] [Related]
37. Regulation of estrogen receptor α by histone methyltransferase SMYD2-mediated protein methylation.
Zhang X; Tanaka K; Yan J; Li J; Peng D; Jiang Y; Yang Z; Barton MC; Wen H; Shi X
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17284-9. PubMed ID: 24101509
[TBL] [Abstract][Full Text] [Related]
38. FOXP1 and estrogen signaling in breast cancer.
Ijichi N; Ikeda K; Horie-Inoue K; Inoue S
Vitam Horm; 2013; 93():203-12. PubMed ID: 23810008
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of histone methyltransferase DOT1L silences ERα gene and blocks proliferation of antiestrogen-resistant breast cancer cells.
Nassa G; Salvati A; Tarallo R; Gigantino V; Alexandrova E; Memoli D; Sellitto A; Rizzo F; Malanga D; Mirante T; Morelli E; Nees M; Åkerfelt M; Kangaspeska S; Nyman TA; Milanesi L; Giurato G; Weisz A
Sci Adv; 2019 Feb; 5(2):eaav5590. PubMed ID: 30775443
[TBL] [Abstract][Full Text] [Related]
40. Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells.
Barone I; Catalano S; Gelsomino L; Marsico S; Giordano C; Panza S; Bonofiglio D; Bossi G; Covington KR; Fuqua SA; Andò S
Cancer Res; 2012 Mar; 72(6):1416-27. PubMed ID: 22282662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
